Biosimilars of anti-tumour necrosis factor (TNF)-α agents have now become clinically available for the treatment of inflammatory bowel diseases (IBD). ⋯ CT-P13 was associated with excellent clinical efficacy and safety profile, supporting its use in the treatment of IBD.
read on…
or not…